long-acting Octreotide.
Phase 3Peptide
long-acting Octreotide. is one of 46 small molecule programs targeting Pancreatic Neuroendocrine Tumor. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
60 competitors in Pancreatic Neuroendocrine Tumor
#DrugCompanyPhaseTrials
1DTIC-Dome
BayerApproved
Afinitor
NovartisPhase 3
Glucophage
EMD SeronoApproved
Sandostatin
Sun PharmaApproved
Octreotide
Johnson & JohnsonPhase 3
Sutent
PfizerPhase 2
FOLFOX
AstraZenecaPhase 3
Ibrance
PfizerPhase 2
Sandostatin
NovartisPhase 2
Thalomid
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for long-acting Octreotide.. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details